Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
RESEARCH TRIANGLE PARK, N.C., Feb. 02, 2016 -- G1 Therapeutics, Inc., a clinical-stage oncology company, announced today that Chief Executive Officer Mark Velleca, MD, PhD, will present a company overview at the 18th Annual BIO CEO & Investor Conference. The presentation will take place on Tuesday, February 9 at 1:30 p.m. ET at the Waldorf Astoria New York in New York City.
For additional information on the conference, visit: http://www.bio.org/events/conferences/bio-ceo-investor-conference.
About G1 Therapeutics, Inc.
G1 Therapeutics is a clinical-stage oncology company developing novel, small-molecule therapies that address significant unmet needs in patients with cancer. The company is advancing G1T28, a first-in-class drug candidate, and G1T38, a potential best-in-class compound, in multiple oncology indications. G1 is privately held and based in Research Triangle Park, NC.
Visit www.g1therapeutics.com for more information.
Contact: Mark Velleca, MD, PhD G1 Therapeutics 919-213-9838 [email protected] Media: Laura Bagby 6 Degrees Communications 312-448-8098 [email protected]
